(ETON) Eton Pharmaceuticals - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 682m USD | Total Return: 110.9% in 12m

Rare Disease Treatments, Pharmaceuticals, Drug Development
Total Rating 39
Safety 30
Buy Signal 0.25
Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.3
Market Cap: 682M
Avg Turnover: 8.06M USD
ATR: 5.21%
Peers RS (IBD): 78.4
Risk 5d forecast
Volatility78.3%
Rel. Tail Risk-22.5%
Reward TTM
Sharpe Ratio1.36
Alpha84.12
Character TTM
Beta0.534
Beta Downside1.343
Drawdowns 3y
Max DD45.65%
CAGR/Max DD2.03
EPS (Earnings per Share) EPS (Earnings per Share) of ETON over the last years for every Quarter: "2021-03": 0.19, "2021-06": -0.1, "2021-09": -0.24, "2021-12": 0.04, "2022-03": -0.21, "2022-06": -0.06, "2022-09": -0.12, "2022-12": 0.04, "2023-03": -0.1, "2023-06": 0.15, "2023-09": -0.02, "2023-12": -0.09, "2024-03": -0.03, "2024-06": -0.12, "2024-09": 0.02, "2024-12": -0.02, "2025-03": -0.06, "2025-06": -0.1, "2025-09": 0.04, "2025-12": 0.19, "2026-03": 0,
EPS CAGR: 18.82%
EPS Trend: 28.6%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of ETON over the last years for every Quarter: 2021-03: 11.897, 2021-06: 3.067, 2021-09: 0.775, 2021-12: 6.093, 2022-03: 2.176, 2022-06: 7.358, 2022-09: 3.219, 2022-12: 8.498, 2023-03: 5.304, 2023-06: 11.997, 2023-09: 7.028, 2023-12: 7.313, 2024-03: 7.966, 2024-06: 9.074, 2024-09: 10.324, 2024-12: 11.647, 2025-03: 17.282, 2025-06: 18.928, 2025-09: 22.459, 2025-12: 21.281, 2026-03: null,
Rev. CAGR: 83.69%
Rev. Trend: 81.0%
Last SUE: 0.64
Qual. Beats: 0
Warnings

choppy

Tailwinds

No distinct edge detected

Description: ETON Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (ETON) is a pharmaceutical company specializing in treatments for rare diseases. The company commercializes products addressing conditions such as severe primary IGF-1 deficiency, adrenal insufficiency, Wilson disease, phenylketonuria, N-acetylglutamate synthase deficiency, homocystinuria, and tyrosinemia type 1. The rare disease sector often benefits from orphan drug designations, which can provide market exclusivity and other incentives.

ETONs pipeline includes late-stage product candidates for adrenal insufficiency, diabetes insipidus, neonatal diabetes mellitus, Wilson disease, and adrenal crisis. This focus on specialized conditions aligns with a business model that targets smaller patient populations but can command premium pricing due to unmet medical needs.

Eton Pharmaceuticals, Inc. was founded in 2017 and is headquartered in Deer Park, Illinois. Further analysis of ETONs financial performance and market position is available on ValueRay.

Headlines to Watch Out For
  • Rare disease product sales drive revenue growth
  • Pipeline development success impacts future valuation
  • Regulatory approvals critical for new drug commercialization
  • Competition in rare disease market affects pricing power
Piotroski VR‑10 (Strict) 5.5
Net Income: -4.60m TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA 0.85 > 1.0
NWC/Revenue: 27.63% < 20% (prev 54.02%; Δ -26.39% < -1%)
CFO/TA 0.11 > 3% & CFO 10.5m > Net Income -4.60m
Net Debt (-16.7m) to EBITDA (3.83m): -4.36 < 3
Current Ratio: 1.57 > 1.5 & < 3
Outstanding Shares: last quarter (26.9m) vs 12m ago 2.95% < -2%
Gross Margin: 53.46% > 18% (prev 0.60%; Δ 5.29k% > 0.5%)
Asset Turnover: 95.04% > 50% (prev 51.25%; Δ 43.80% > 0%)
Interest Coverage Ratio: -0.05 > 6 (EBITDA TTM 3.83m / Interest Expense TTM 4.78m)
Altman Z'' -4.22
A: 0.24 (Total Current Assets 60.6m - Total Current Liabilities 38.5m) / Total Assets 92.1m
B: -1.22 (Retained Earnings -112.5m / Total Assets 92.1m)
C: -0.00 (EBIT TTM -217k / Avg Total Assets 84.1m)
D: -1.71 (Book Value of Equity -112.5m / Total Liabilities 66.0m)
Altman-Z'' Score: -4.22 = D
Beneish M -2.43
DSRI: 1.07 (Receivables 11.8m/5.36m, Revenue 80.0m/39.0m)
GMI: 1.12 (GM 53.46% / 60.01%)
AQI: 0.73 (AQ_t 0.34 / AQ_t-1 0.46)
SGI: 2.05 (Revenue 80.0m / 39.0m)
TATA: -0.16 (NI -4.60m - CFO 10.5m) / TA 92.1m)
Beneish M-Score: -2.43 (Cap -4..+1) = BBB
What is the price of ETON shares? As of April 06, 2026, the stock is trading at USD 24.99 with a total of 472,326 shares traded.
Over the past week, the price has changed by +10.67%, over one month by +45.00%, over three months by +49.37% and over the past year by +110.89%.
Is ETON a buy, sell or hold? Eton Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ETON.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ETON price?
Wallstreet Target Price 39.3 57.4%
Analysts Target Price 39.3 57.4%
ETON Fundamental Data Overview as of 06 April 2026
P/E Forward = 23.8095
P/S = 8.5283
P/B = 26.0702
Revenue TTM = 80.0m USD
EBIT TTM = -217k USD
EBITDA TTM = 3.83m USD
Long Term Debt = 21.8m USD (from longTermDebt, last quarter)
Short Term Debt = 8.79m USD (from shortTermDebt, last quarter)
Debt = 9.25m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -16.7m USD (from netDebt column, last quarter)
Enterprise Value = 665.1m USD (681.8m + Debt 9.25m - CCE 25.9m)
Interest Coverage Ratio = -0.05 (Ebit TTM -217k / Interest Expense TTM 4.78m)
EV/FCF = -1000.0x (Enterprise Value 665.1m / FCF TTM -333k)
FCF Yield = -0.05% (FCF TTM -333k / Enterprise Value 665.1m)
FCF Margin = -0.42% (FCF TTM -333k / Revenue TTM 80.0m)
Net Margin = -5.75% (Net Income TTM -4.60m / Revenue TTM 80.0m)
Gross Margin = 53.46% ((Revenue TTM 80.0m - Cost of Revenue TTM 37.2m) / Revenue TTM)
Gross Margin QoQ = 61.56% (prev 34.97%)
Tobins Q-Ratio = 7.22 (Enterprise Value 665.1m / Total Assets 92.1m)
Interest Expense / Debt = 13.06% (Interest Expense 1.21m / Debt 9.25m)
Taxrate = 21.0% (US default 21%)
NOPAT = -171k (EBIT -217k * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.57 (Total Current Assets 60.6m / Total Current Liabilities 38.5m)
Debt / Equity = 0.35 (Debt 9.25m / totalStockholderEquity, last quarter 26.2m)
Debt / EBITDA = -4.36 (Net Debt -16.7m / EBITDA 3.83m)
 Debt / FCF = 50.13 (negative FCF - burning cash) (Net Debt -16.7m / FCF TTM -333k)
 Total Stockholder Equity = 24.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.47% (Net Income -4.60m / Total Assets 92.1m)
RoE = -18.84% (Net Income TTM -4.60m / Total Stockholder Equity 24.4m)
RoCE = -0.47% (EBIT -217k / Capital Employed (Equity 24.4m + L.T.Debt 21.8m))
 RoIC = -0.31% (negative operating profit) (NOPAT -171k / Invested Capital 54.7m)
 WACC = 7.89% (E(681.8m)/V(691.1m) * Re(7.86%) + D(9.25m)/V(691.1m) * Rd(13.06%) * (1-Tc(0.21)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 2.24%
 [DCF] Fair Price = unknown (Cash Flow -333k)
 EPS Correlation: 28.58 | EPS CAGR: 18.82% | SUE: -4.0 | # QB: 0
Revenue Correlation: 80.98 | Revenue CAGR: 83.69% | SUE: 0.64 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.20 | Chg7d=-0.050 | Chg30d=-0.030 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=0.84 | Chg7d=-0.095 | Chg30d=-0.170 | Revisions Net=-1 | Growth EPS=+162.5% | Growth Revenue=+38.1%
EPS next Year (2027-12-31): EPS=1.56 | Chg7d=-0.050 | Chg30d=+0.110 | Revisions Net=+1 | Growth EPS=+85.7% | Growth Revenue=+47.2%
External Resources
Dataroma Stockcircle